Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors A. Zeidan, P. Becker, P. Patel, G. Schiller, M.L. Tsai, T. Lin, E. Wang, M. Erlander,J. Cortes
Title Polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with low-dose cytarabine or decitabine in patients with relapsed/refractory acute myeloid leukaemia in phase Ib
Journal
Vol
Issue
Date
URL https://www.annalsofoncology.org/article/S0923-7534(19)59279-1/fulltext
Abstract Text Annals of Oncology30 (Supplement 5): v435–v448, 2019, doi:10.1093/annonc/mdz251

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown acute myeloid leukemia not applicable Decitabine + Onvansertib Phase I Actionable In a Phase I trial, Onvansertib (PCM-075) and Dacogen (decitabine) combination therapy resulted in complete response in 33.3% (2/6) and complete response with incomplete hematologic remission in 16.7% (1/6) of evaluable patients with relapsed or refractory acute myeloid leukemia (Ann Oncol, 30 (Supplement 5): v435-v448, 2019; NCT03303339). detail...
Unknown unknown acute myeloid leukemia not applicable Cytarabine + Onvansertib Phase I Actionable In a Phase I trial, Onvansertib (PCM-075) and low-dose Cytosar-U (cytarabine) combination therapy resulted in complete response in 33.3% (1/3) of evaluable patients with relapsed or refractory acute myeloid leukemia (Ann Oncol, 30 (Supplement 5): v435-v448, 2019; NCT03303339). detail...